Tenderwize
Zurück zur Suche

Open-house rebate agreement for Buserelin

AOK Bayern - Die Gesundheitskasse·München, Germany·Deadline Dec 05, 2026 · 99 days left·Open·Supplies·Framework
Registrieren zum SpeichernOpen documents
Originaltitel der Bekanntmachung

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Buserelin, ATC L02AE01

46/100

Opportunity Score

Needs reviewMedium complexity
SuppliesFrameworkOpen
Warum diese Bewertung?

Chance

46 / 100

Komplexität

58 / 100

Risikofaktoren

The buyer explicitly states this is an open-house model and not a standard competitive procurement procedure, so usual...

Submission format is strict: either handwritten paper originals in duplicate or electronic submission with a qualified...

Tiefe Portfolioanalyse

Tiefe Analyse der Unternehmenspassung

Verwendet:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Überblick

Moderate opportunity

Wichtige Fakten

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Jan 2027
  • Non-exclusive open-house rebate agreements for the active substance Buserelin (ATC L02AE01).
  • Supply of pharmaceutical products under a pre-defined contract model.
Vollständige Zusammenfassung anzeigen

This is an open-house pharmaceutical supply arrangement for Buserelin (ATC L02AE01) offered by AOK Bayern. It is not a competitive award procedure in the usual sense: the buyer states that no selection among bidders is made and that any pharmaceutical company meeting the stated eligibility conditions may join on identical, non-negotiable terms. The contract term runs from 2025-02-01 to 2027-01-31, with contract entry possible until 2026-12-05. Submission is allowed electronically with a qualified electronic signature or in paper form; documents not in German must be submitted with a German translation. Procurement documents are available via DTVP, but only the notice text was analyzed, not the full document set.

Risiken

The buyer explicitly states this is an open-house model and not a standard competitive procurement procedure, so usual...

Submission format is strict: either handwritten paper originals in duplicate or electronic submission with a qualified...

Analyse kann unvollständig sein

Nur ein Teil der Vergabeunterlagen wurde analysiert. Weitere Anforderungen, Zertifikate oder Einreichungsdokumente können in den übrigen Unterlagen enthalten sein.

Wichtige Anforderungen

Technical

  • If the signatory is not authorized in the commercial register, a power of attorney must be provided.

Administrative

  • Submit a signed declaration of reliability (Eigenerklärung zur Zuverlässigkeit).
  • Submit the completed and signed contract and the completed and signed annex 'Festlegung der vertragsgegenständlichen Arzneimittel'.

Auftraggeber

Ort

München, DEU

Website

www.aok.de

Auftraggeberprofil

Profil öffnen

Kennung

DE811695320

Tätigkeit

Health

Lose (1)

LOT-0001

Open-house rebate agreement for Buserelin

Single lot covering non-exclusive open-house rebate agreements for the medicinal product Buserelin, ATC L02AE01. The scope is pharmaceutical products/supplies in Germany, with performance in Bavaria (DE212). The notice says the contract terms are pre-set and not individually negotiable.

SuppliesFrameworkEU fundedElectronic submission

Ort

DE212, Germany

Dauer

Jan 2025 - Jan 2027

Kategorie

Pharmaceutical products

Frist

Deadline Dec 05, 2026

Vergabedetails

Veröffentlichungsdatum
15 Dec 2024
Sprachen
German

Referenzmetadaten

Rechtsgrundlage
32014L0024

Referenz-IDs

Ausschreibungs-ID
768779-2024

Dokumente (2)

Vergabedokument 1Einreichungsportal 1

Ähnliche Ausschreibungen

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30